{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:49:56Z","timestamp":1792460996084,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10620-024-08802-1","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T11:32:31Z","timestamp":1735212751000},"page":"728-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic Drug Monitoring in Patients with Ulcerative Colitis on Infliximab: A Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"70","author":[{"given":"Paul","family":"Dupenloup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadit P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Goldhaber-Fiebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Streett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Brandeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant E.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"8802_CR1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u20132778.","journal-title":"Lancet."},{"key":"8802_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/gut.2005.088732","volume":"56","author":"P Rutgeerts","year":"2007","unstructured":"Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453\u2013455.","journal-title":"Gut."},{"key":"8802_CR3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","volume":"141","author":"JF Colombel","year":"2011","unstructured":"Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194\u20131201.","journal-title":"Gastroenterology."},{"key":"8802_CR4","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.","journal-title":"Clin Transl Gastroenterol."},{"key":"8802_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/ecco-jcc\/jjv061","volume":"9","author":"X Roblin","year":"2015","unstructured":"Roblin X, Marotte H, Leclerc M et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis. 2015;9:525\u2013531.","journal-title":"J Crohns Colitis."},{"key":"8802_CR6","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-1329.e1323.","journal-title":"Gastroenterology"},{"key":"8802_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ibd\/izz131","volume":"26","author":"SR Fernandes","year":"2020","unstructured":"Fernandes SR, Bernardo S, Sim\u00f5es C et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26:263\u2013270.","journal-title":"Inflamm Bowel Dis."},{"key":"8802_CR8","first-page":"50","volume":"2","author":"N Syed","year":"2020","unstructured":"Syed N, Tolaymat M, Brown SA et al. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab reatment and lower healthcare utilization compared with reactive and clinical monitoring. Crohns Colitis 360 2020;2:50. (Author names in bold designate shared co-first authorship)","journal-title":"Crohns Colitis 360"},{"key":"8802_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/ecco-jcc\/jjaa029","volume":"14","author":"R Shah","year":"2020","unstructured":"Shah R, Hoffman GR, El-Dallal M et al. Is therapeutic drug monitoring for anti-tumour necrosis factor agents in adults with inflammatory bowel disease ready for standard of care? A systematic review and meta-analysis. J Crohns Colitis. 2020;14:1057\u20131065. (Author names in bold designate shared co-first authorship)","journal-title":"J Crohns Colitis."},{"key":"8802_CR10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","volume":"15","author":"K Papamichael","year":"2017","unstructured":"Papamichael K, Chachu KA, Vajravelu RK et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15:1580-1588.e1583.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8802_CR11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827\u2013834.","journal-title":"Gastroenterology."},{"key":"8802_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ibd\/izz113","volume":"26","author":"DM Negoescu","year":"2020","unstructured":"Negoescu DM, Enns EA, Swanhorst B et al. Proactive vs reactive therapeutic drug monitoring of infliximab in Crohn\u2019s disease: a cost-effectiveness analysis in a simulated cohort. Inflamm Bowel Dis. 2020;26:103\u2013111.","journal-title":"Inflamm Bowel Dis."},{"key":"8802_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","volume":"63","author":"B Ungar","year":"2014","unstructured":"Ungar B, Chowers Y, Yavzori M et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258\u20131264.","journal-title":"Gut."},{"key":"8802_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/joim.13495","volume":"292","author":"MK Brun","year":"2022","unstructured":"Brun MK, Goll GL, J\u00f8rgensen KK et al. Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial. J Intern Med. 2022;292:477\u2013491.","journal-title":"J Intern Med."},{"key":"8802_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40273-019-00837-x","volume":"37","author":"F Alarid-Escudero","year":"2019","unstructured":"Alarid-Escudero F, Krijkamp EM, Pechlivanoglou P et al. A need for change! a coding framework for improving transparency in decision modeling. Pharmacoeconomics. 2019;37:1329\u20131339.","journal-title":"Pharmacoeconomics."},{"key":"8802_CR16","first-page":"1","volume":"58","author":"E Arias","year":"2010","unstructured":"Arias E. United States life tables, 2006. Natl Vital Stat Rep. 2010;58:1\u201340.","journal-title":"Natl Vital Stat Rep."},{"key":"8802_CR17","unstructured":"Agency for Healthcare Research and Quality. Number of people in thousands, United States, 1996\u20132018 Accessed at on 9 November 2023."},{"key":"8802_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/apt.12844","volume":"40","author":"C Nordenvall","year":"2014","unstructured":"Nordenvall C, Ekbom A, Bottai M et al. Mortality after total colectomy in 3084 patients with inflammatory bowel disease: a population-based cohort study. Aliment Pharmacol Ther. 2014;40:280\u2013287.","journal-title":"Aliment Pharmacol Ther."},{"key":"8802_CR19","unstructured":"IBM Micromedex\u00ae Red Book, Truven Health Analytics (2021). ."},{"key":"8802_CR20","unstructured":"Center for Medicare & Medicaid Services. Physician Fee Schedule Search."},{"key":"8802_CR21","unstructured":"Center for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule."},{"key":"8802_CR22","doi-asserted-by":"publisher","first-page":"otab029","DOI":"10.1093\/crocol\/otab029","volume":"3","author":"S Weissman","year":"2021","unstructured":"Weissman S, Sharma S, Fung BM et al. Increased mortality and healthcare costs upon hospital readmissions of ulcerative colitis flares: a large population-based cohort study. Crohns Colitis 360 2021;3:otab029. (Author names in bold designate shared co-first authorship)","journal-title":"Crohns Colitis 360"},{"key":"8802_CR23","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/DCR.0b013e3181b327a6","volume":"52","author":"SD Holubar","year":"2009","unstructured":"Holubar SD, Long KH, Loftus EV Jr et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County. Minnesota. Dis Colon Rectum. 2009;52:1815\u20131823.","journal-title":"Minnesota. Dis Colon Rectum."},{"key":"8802_CR24","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.surg.2016.10.019","volume":"161","author":"AL Chang","year":"2017","unstructured":"Chang AL, Kim Y, Ertel AE et al. Case mix-adjusted cost of colectomy at low-, middle-, and high-volume academic centers. Surgery. 2017;161:1405\u20131413.","journal-title":"Surgery."},{"key":"8802_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10198-009-0199-5","volume":"11","author":"YS Punekar","year":"2010","unstructured":"Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ. 2010;11:67\u201376.","journal-title":"Eur J Health Econ."},{"key":"8802_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer J, Lawrence WF, Anderson JP et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26:391\u2013400.","journal-title":"Med Decis Making."},{"key":"8802_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u20131103.","journal-title":"JAMA."},{"key":"8802_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/1475-6773.12612","volume":"53","author":"A Dunn","year":"2018","unstructured":"Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53:175\u2013196.","journal-title":"Health Serv Res."},{"key":"8802_CR29","unstructured":"Agency for Healthcare Research and Quality. Using appropriate price indices for expenditure comparisons. Accessed at www.meps.ahrq.gov\/about_meps\/Price_Index.shtml on 9 November 2023."},{"key":"8802_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group\u20136. Med Decis Making. 2012;32:722\u2013732.","journal-title":"Med Decis Making."},{"key":"8802_CR31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/0272989X15605091","volume":"36","author":"JD Goldhaber-Fiebert","year":"2016","unstructured":"Goldhaber-Fiebert JD, Jalal HJ. Some health states are better than others: using health state rank order to improve probabilistic analyses. Med Decis Making. 2016;36:927\u2013940.","journal-title":"Med Decis Making."},{"key":"8802_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257\u2013265.","journal-title":"Gastroenterology."},{"key":"8802_CR33","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u20131214.","journal-title":"N Engl J Med."},{"key":"8802_CR34","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u20131736.","journal-title":"N Engl J Med."},{"key":"8802_CR35","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u20132128.","journal-title":"Lancet."},{"key":"8802_CR36","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/ecco-jcc\/jjy039","volume":"12","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Vajravelu RK, Vaughn BP et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12:804\u2013810.","journal-title":"J Crohns Colitis."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08802-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T18:40:45Z","timestamp":1739990445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08802-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["8802"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08802-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}